Do analysts recommend EVTV or NEPH?

Nephros has a consensus target price of $4.00, indicating a potential downside of 12.09%. Given Nephros' stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Envirotech Vehicles. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Envirotech Vehicles 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nephros 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is EVTV or NEPH more profitable?

Nephros has a net margin of 8.38% compared to Envirotech Vehicles' net margin of -382.71%. Nephros' return on equity of 10.60% beat Envirotech Vehicles' return on equity. Company Net Margins Return on Equity Return on Assets Envirotech Vehicles -382.71% -1,284.22% -181.53% Nephros 8.38% 10.60% 8.05%

Do analysts recommend RVP or NEPH?

Nephros has a consensus price target of $4.00, indicating a potential downside of 12.09%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nephros 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer LUCY or NEPH?

Nephros has a consensus price target of $4.00, indicating a potential downside of 12.09%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Nephros 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, NEPH or BMRA?

Nephros has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.63 $1.19M $0.16 28.44 Biomerica $5.31M 1.25 -$4.97M -$0.89 N/A

Is NEPH or BMRA more profitable?

Nephros has a net margin of 8.38% compared to Biomerica's net margin of -96.49%. Nephros' return on equity of 10.60% beat Biomerica's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 8.38% 10.60% 8.05% Biomerica -96.49% -98.14% -70.42%

Nephros (NEPH) Competitors

$4.55 +0.24 (+5.57%)

As of 08/28/2026 04:00 PM Eastern

Compare

NEPH vs. RMTI, EVTV, RVP, LUCY, and BMRA

Should you buy Nephros stock or one of its competitors? Nephros's main competitors and comparable companies include Rockwell Medical (RMTI), Envirotech Vehicles (EVTV), Retractable Technologies (RVP), Innovative Eyewear (LUCY), and Biomerica (BMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Nephros compare to Rockwell Medical?

Rockwell Medical (NASDAQ:RMTI) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Rockwell Medical had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for Rockwell Medical and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat Rockwell Medical's score of 1.87 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Rockwell Medical	Very Positive
Nephros	Very Positive

Nephros has lower revenue, but higher earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rockwell Medical	$69.26M	0.48	-$5.31M	-$1.34	N/A
Nephros	$18.79M	2.63	$1.19M	$0.16	28.44

Rockwell Medical has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

Nephros has a net margin of 8.38% compared to Rockwell Medical's net margin of -7.33%. Nephros' return on equity of 10.60% beat Rockwell Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rockwell Medical	-7.33%	-14.03%	-8.90%
Nephros	8.38%	10.60%	8.05%

Rockwell Medical currently has a consensus price target of $20.00, indicating a potential upside of 144.80%. Nephros has a consensus price target of $4.00, indicating a potential downside of 12.09%. Given Rockwell Medical's higher probable upside, equities research analysts clearly believe Rockwell Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rockwell Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 4.6% of Rockwell Medical shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nephros beats Rockwell Medical on 11 of the 15 factors compared between the two stocks.

How does Nephros compare to Envirotech Vehicles?

Envirotech Vehicles (NASDAQ:EVTV) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Nephros had 1 more articles in the media than Envirotech Vehicles. MarketBeat recorded 1 mentions for Nephros and 0 mentions for Envirotech Vehicles. Nephros' average media sentiment score of 1.89 beat Envirotech Vehicles' score of 0.00 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Envirotech Vehicles	Neutral
Nephros	Very Positive

Envirotech Vehicles has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Nephros has a consensus target price of $4.00, indicating a potential downside of 12.09%. Given Nephros' stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Envirotech Vehicles.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envirotech Vehicles	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Nephros has higher revenue and earnings than Envirotech Vehicles. Envirotech Vehicles is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envirotech Vehicles	$5.94M	4.24	-$39.13M	-$6.45	N/A
Nephros	$18.79M	2.63	$1.19M	$0.16	28.44

Nephros has a net margin of 8.38% compared to Envirotech Vehicles' net margin of -382.71%. Nephros' return on equity of 10.60% beat Envirotech Vehicles' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envirotech Vehicles	-382.71%	-1,284.22%	-181.53%
Nephros	8.38%	10.60%	8.05%

5.7% of Envirotech Vehicles shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 17.8% of Envirotech Vehicles shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nephros beats Envirotech Vehicles on 14 of the 16 factors compared between the two stocks.

How does Nephros compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Nephros has lower revenue, but higher earnings than Retractable Technologies. Retractable Technologies is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$33.90M	0.64	-$7.01M	-$0.12	N/A
Nephros	$18.79M	2.63	$1.19M	$0.16	28.44

Nephros has a net margin of 8.38% compared to Retractable Technologies' net margin of -41.11%. Nephros' return on equity of 10.60% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
Nephros	8.38%	10.60%	8.05%

Retractable Technologies has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nephros has a consensus price target of $4.00, indicating a potential downside of 12.09%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Nephros had 1 more articles in the media than Retractable Technologies. MarketBeat recorded 1 mentions for Nephros and 0 mentions for Retractable Technologies. Nephros' average media sentiment score of 1.89 beat Retractable Technologies' score of 0.00 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Retractable Technologies	Neutral
Nephros	Very Positive

Summary

Nephros beats Retractable Technologies on 14 of the 16 factors compared between the two stocks.

How does Nephros compare to Innovative Eyewear?

Innovative Eyewear (NASDAQ:LUCY) and Nephros (NASDAQ:NEPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by insiders. Comparatively, 6.7% of Nephros shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Innovative Eyewear had 16 more articles in the media than Nephros. MarketBeat recorded 17 mentions for Innovative Eyewear and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat Innovative Eyewear's score of -0.42 indicating that Nephros is being referred to more favorably in the news media.

Company	Overall Sentiment
Innovative Eyewear	Neutral
Nephros	Very Positive

Nephros has higher revenue and earnings than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66M	3.08	-$7.59M	-$1.29	N/A
Nephros	$18.79M	2.63	$1.19M	$0.16	28.44

Nephros has a net margin of 8.38% compared to Innovative Eyewear's net margin of -225.26%. Nephros' return on equity of 10.60% beat Innovative Eyewear's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-225.26%	-88.90%	-80.34%
Nephros	8.38%	10.60%	8.05%

Innovative Eyewear has a beta of 2.72, suggesting that its stock price is 172% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Nephros has a consensus price target of $4.00, indicating a potential downside of 12.09%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Nephros beats Innovative Eyewear on 13 of the 16 factors compared between the two stocks.

How does Nephros compare to Biomerica?

Nephros (NASDAQ:NEPH) and Biomerica (NASDAQ:BMRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Nephros has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.63	$1.19M	$0.16	28.44
Biomerica	$5.31M	1.25	-$4.97M	-$0.89	N/A

Nephros presently has a consensus target price of $4.00, suggesting a potential downside of 12.09%. Biomerica has a consensus target price of $9.00, suggesting a potential upside of 320.56%. Given Biomerica's higher probable upside, analysts clearly believe Biomerica is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nephros has a net margin of 8.38% compared to Biomerica's net margin of -96.49%. Nephros' return on equity of 10.60% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	8.38%	10.60%	8.05%
Biomerica	-96.49%	-98.14%	-70.42%

In the previous week, Biomerica had 7 more articles in the media than Nephros. MarketBeat recorded 8 mentions for Biomerica and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat Biomerica's score of 1.22 indicating that Nephros is being referred to more favorably in the media.

Company	Overall Sentiment
Nephros	Very Positive
Biomerica	Positive

Nephros has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Biomerica has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

41.1% of Nephros shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 6.7% of Nephros shares are held by company insiders. Comparatively, 18.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nephros beats Biomerica on 13 of the 16 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.81M	$5.80B	$7.24B	$12.93B
Dividend Yield	N/A	1.76%	2.54%	11.02%
P/E Ratio	28.44	25.80	271.50	25.41
Price / Sales	2.63	68.39	624.07	96.99
Price / Cash	34.36	32.99	79.29	54.21
Price / Book	4.14	6.18	12.95	6.14
Net Income	$1.19M	$148.22M	$3.46B	$347.93M
7 Day Performance	11.52%	-0.26%	-0.11%	-0.78%
1 Month Performance	40.43%	7.91%	8.32%	5.60%
1 Year Performance	21.98%	6.20%	24.64%	15.64%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	2.9294 of 5 stars	$4.55 +5.6%	$4.00 -12.1%	+12.9%	$46.81M	$18.79M	28.44	30
RMTI Rockwell Medical	3.6239 of 5 stars	$8.31 +4.5%	$20.00 +140.6%	-54.6%	$33.49M	$69.26M	N/A	300	Positive News
EVTV Envirotech Vehicles	N/A	$1.95 +0.3%	N/A	-15.0%	$25.16M	$5.94M	N/A	10
RVP Retractable Technologies	N/A	$0.72 -2.2%	N/A	-13.1%	$21.53M	$33.90M	N/A	240
LUCY Innovative Eyewear	0.7591 of 5 stars	$1.16 +7.9%	N/A	-51.0%	$9.95M	$2.66M	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. RMTI, EVTV, RVP, LUCY, and BMRA

How does Nephros compare to Rockwell Medical?

Summary

How does Nephros compare to Envirotech Vehicles?

Summary

How does Nephros compare to Retractable Technologies?

Summary

How does Nephros compare to Innovative Eyewear?

Summary

How does Nephros compare to Biomerica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. RMTI, EVTV, RVP, LUCY, and BMRA

How does Nephros compare to Rockwell Medical?

Does the media refer more to RMTI or NEPH?

Which has stronger valuation and earnings, RMTI or NEPH?

Which has more volatility and risk, RMTI or NEPH?

Is RMTI or NEPH more profitable?

Do analysts prefer RMTI or NEPH?

Do insiders & institutionals hold more shares of RMTI or NEPH?

Summary

How does Nephros compare to Envirotech Vehicles?

Does the media refer more to EVTV or NEPH?

Which has more volatility and risk, EVTV or NEPH?

Do analysts recommend EVTV or NEPH?

Which has stronger valuation & earnings, EVTV or NEPH?

Is EVTV or NEPH more profitable?

Do institutionals and insiders have more ownership in EVTV or NEPH?

Summary

How does Nephros compare to Retractable Technologies?

Which has better earnings and valuation, RVP or NEPH?

Is RVP or NEPH more profitable?

Which has more risk & volatility, RVP or NEPH?

Do institutionals & insiders have more ownership in RVP or NEPH?

Do analysts recommend RVP or NEPH?

Does the media refer more to RVP or NEPH?

Summary

How does Nephros compare to Innovative Eyewear?

Do institutionals and insiders have more ownership in LUCY or NEPH?

Does the media favor LUCY or NEPH?

Which has better valuation & earnings, LUCY or NEPH?

Is LUCY or NEPH more profitable?

Which has more risk & volatility, LUCY or NEPH?

Do analysts prefer LUCY or NEPH?

Summary

How does Nephros compare to Biomerica?

Which has stronger valuation and earnings, NEPH or BMRA?

Do analysts recommend NEPH or BMRA?

Is NEPH or BMRA more profitable?

Does the media refer more to NEPH or BMRA?

Which has more risk & volatility, NEPH or BMRA?

Do institutionals & insiders believe in NEPH or BMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools